Corcept Therapeutics GAAP EPS of $0.20 misses by $0.07, revenue of $202.1M misses by $52.84M
Source: SeekingAlpha
2026-02-24 16:26:10 ET
More on Corcept Therapeutics
- Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not
- Why Corcept Therapeutics' Relacorilant Fell Short And What It Means For The Company
- Corcept: Korlym Defies Generics As Relacorilant Hits An FDA CRL (Rating Upgrade)
- Corcept Therapeutics Q4 2025 Earnings Preview
- Quant snapshot: Amerigo, Allianz lead strong buys as Ashford Hospitality, Hudson Pacific lag
Read the full article on Seeking Alpha
For further details see:
Corcept Therapeutics GAAP EPS of $0.20 misses by $0.07, revenue of $202.1M misses by $52.84M
Corcept Therapeutics Incorporated
NASDAQ: CORT
CORT Trading
0.75% G/L:
$33.71 Last:
300,393 Volume:
$33.47 Open:
CORT Latest News
March 10, 2026 06:00:00 pm
REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026
March 03, 2026 10:03:29 am
Investors of Corcept Therapeutics, Inc. (CORT) Seeking Recovery - Contact Kaplan Fox Before Deadline on April 21, 2026
CORT Stock Data
$4,351,636,537
83,309,068
0.22%
163
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
